

RECEIVED
CENTRAL FAX CENTERvon BORSTEL et al.. - Appln. No. 08/460,186
February 26, 2009

FEB 26 2009

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for treating toxicity due to a pyrimidine nucleoside analog comprising administering to an animal a pharmaceutically effective amount of an acylated derivative of uridine selected from the group consisting of triacetyluridine and ethoxycarbonyluridine or ~~cytidine~~ triacetylcytidine, wherein said pyrimidine nucleoside analog is selected from the group consisting of 5-fluorouracil (5-FU), Tegafur, 5-fluoroorotate, 5'-deoxy-5-fluorouridine, 5-fluorouridine, 2'-deoxy-5-fluorouridine, fluorocytosine, trifluoromethyl-2'-deoxyuridine, arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine, N-phosphonoacetyl-L-aspartic acid (PALA), pyrazofurin, 6-azauridine, azaribine, thymidine, 3-deazauridine, AZT, dideoxycytidine, 5-ethyl-2'-deoxyuridine, 5-iodo-2'-deoxyuridine, 5-bromo-2'-deoxyuridine, 5-methylamino-2'-deoxyuridine, arabinosyluracil, dideoxyuridine and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.

2. (canceled)

3. (original) A method as in claim 1 wherein said toxicity is damage to hematopoietic tissue.

von BORSTEL et al. -- Appln. No. 08/460,186
February 26, 2009

4. (original) A method as in claim 1 wherein said toxicity is damage to mucosal tissues.

5-17. (canceled)

18. (currently amended) A method as in claim 1 wherein said administering step also includes administering an inhibitor of uridine phosphorylase selected from the group consisting of benzylacyclouridine, benzyloxybenzylacyclo-uridine, aminomethyl-benzylacyclouridine, aminomethyl-benzyloxybenzylacyclo-uridine, hydroxymethyl-benzylacyclouridine, and hydroxymethyl-benzyloxybenzylacyclouridine, 2,2'-anhydro-5-ethyluridine, 5-benzyl barbiturate, 5-benzyloxybenzyl barbiturate, 5-benzyloxybenzyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, 5-benzyloxybenzylacetyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, and 5-methoxybenzylacetylacyclobarbiturate.

19. (canceled)

20. (currently amended) A method as in claim 1 wherein said acylated derivative is ~~an acylated derivative of cytidine~~ triacetylcytidine, and said administering step also includes administering an inhibitor of cytidine deaminase selected from the group consisting of tetrahydrouridine or tetrahydro-2'-deoxyuridine.

21. (canceled)

von BORSTEL et al.. – Appln. No. 08/460,186
February 26, 2009

22. (currently amended) A method as in claim 1 wherein said administering step also includes administering an inhibitor of nucleoside transport selected from the group consisting of dipyridamole, probenecid, lidoflazine and nitrobenzylthioinosine.

23. (canceled)

24. (currently amended) A method as in claim 1 wherein said administering step also includes administering an agent which enhances hematopoiesis selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, stem cell factor, erythropoietin, glucan, polyinosine-polycytidine.

25. (currently amended) A method as in claim 1 wherein said administering step also includes administering a compound capable of enhancing the uptake and phosphorylation of nucleosides into cells selected from the group consisting of insulin and insulinogenic carbohydrate.